Off the Kuff Rotating Header Image

Corbevax

Very cool.

A Houston-made COVID-19 vaccine will likely be approved for use in India by the end of the year, said Dr. Peter Hotez, co-director of Texas Children’s Hospitals Center for Vaccine Development.

Hotez and his co-director, Dr. Maria Elena Bottazzi, created the vaccine as a cheap and easy-to-produce option to fill global gaps in vaccine coverage. Dubbed Corbevax, it uses a safe and traditional vaccine technology, called recombinant protein subunit, that has been used for decades in the hepatitis B vaccine and is therefore easier for other countries to make themselves.

Drug maker Biological E has agreed to manufacture 300 million doses in India, where 36 percent of the population is fully vaccinated and 59 percent have at least one dose. Efficacy data has been submitted to the Drugs Controller General of India for authorization.

The vaccine does not have a patent, and Hotez hopes manufacturers in other low- or middle-income countries will take advantage of its availability.

“If you leave large populations unvaccinated, that’s where the greatest concerns of variants arise,” he said, referring to the current spread of the omicron variant from the largely unvaccinated South African population. “So this vaccine is therefore needed not only for global health but also economic development.”

Bottazzi, who is from Honduras, is especially interested in the vaccine’s proliferation throughout Latin America. Less than 40 percent of the population is fully vaccinated in several countries there, according to the New York Times global virus tracker.

“Corbevax is gong to be a trailblazer,” she said.

The work is based on research they had done for a SARS virus but never took to a human trial because the virus had receded by then. Anything we can do to get more shots in arms is absolutely a good thing. Kudos to all for the achievement.

Related Posts:

One Comment

  1. David Fagan says:

    0 days and counting……….